Tenax Therapeutics (TENX) Change in Accured Expenses (2010 - 2026)

Tenax Therapeutics has disclosed Change in Accured Expenses across 17 years of filings, most recently posting $1.0 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $1.0 million, up 268.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 208.93% YoY), and the FY2025 annual result was -$421000.0, down 180.5% from the prior year.
• Change in Accured Expenses came in at $1.0 million for Q1 2026 at Tenax Therapeutics, up from $124000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.0 million in Q2 2025 to a low of -$974000.0 in Q3 2025.
• The 5-year median for Change in Accured Expenses is $57000.0 (2024), against an average of $59944.1.
• Across the five-year window, Change in Accured Expenses plunged 442.26% in 2023 and surged 1717.54% in 2025, its largest moves.
• Tenax Therapeutics' Change in Accured Expenses stood at $529205.0 in 2022, then surged by 89.48% to $1.0 million in 2023, then sank by 44.45% to $557000.0 in 2024, then slumped by 77.74% to $124000.0 in 2025, then jumped by 726.61% to $1.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.0 million (Q1 2026), $124000.0 (Q4 2025), and -$974000.0 (Q3 2025), per Business Quant data.